Amphastar officer proposes $330K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Amphastar Pharmaceuticals, Inc. (AMPH) officer William J Peters reported a proposed sale of 11,000 common shares, with an approximate sale date of November 16, 2026, and an aggregate market value of $329,590. The securities information also lists 11,000 shares acquired that day through exercise of stock options for cash. The listed date for plan adoption or giving of instruction, if relying on Rule 10b5-1, is March 10, 2026. The notice reports three other common-share sales during the preceding three months: 12,631 shares on November 5, 2026, for $47,299 in gross proceeds; 4,139 shares on September 21, 2026, for $103,475; and 16,000 shares on November 4, 2026, for $448,480.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.